Alvotech(ALVO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.56 | Insider Own | 55.53% | Shs Outstand | 356.8M | Perf Week | 1.53% |
| Market Cap | 1.82B | Forward P/E | 20.17 | EPS next Y | 1820.75% | Insider Trans | - | Shs Float | 173.6M | Perf Month | -17.26% |
| Enterprise Value | 3.12B | PEG | - | EPS next Q | -0.02 | Inst Own | 11.08% | Short Float | 3.67% | Perf Quarter | 22.69% |
| Income | -0.18B | P/S | 3.69 | EPS this Y | 86.6% | Inst Trans | 8.16% | Short Ratio | 6.01 | Perf Half Y | 34.39% |
| Sales | 0.49B | P/B | - | EPS next 5Y | - | ROA | -12.05% | Short Interest | 6.36M | Perf YTD | -9.36% |
| Book/sh | -0.54 | P/C | 12.72 | EPS past 3/5Y | - | ROE | - | 52W High | -41.29% ($7.92) | Perf Year | -40.69% |
| Cash/sh | 0.37 | P/FCF | - | Sales past 3/5Y | 91.85% - | ROIC | -14.88% | 52W Low | 58.16% ($2.94) | Perf 3Y | -46.55% |
| Dividend Est. | - | EV/EBITDA | 36.25 | EPS Y/Y TTM | -365.51% | Gross Margin | 60.45% | Volatility(W/M) | 4.26% 5.21% | Perf 5Y | -53.03% |
| Dividend TTM | - | EV/Sales | 6.35 | Sales Y/Y TTM | -12.17% | Oper. Margin | 9.12% | ATR (14) | 0.28 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.96 | EPS Q/Q | -276.37% | Profit Margin | -36.51% | RSI (14) | 38.87 | Recom | 1.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.65 | Sales Q/Q | -38.94% | SMA20 | -10.93% ($5.22) | Beta | 0.21 | Target Price | $7.27 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/11 | SMA50 | -12.52% ($5.32) | Rel Volume | 0.67 | Prev Close | $4.89 |
| Employees | 1460 | LT Debt/Eq | - | EPS/Sales Surpr. | -62.17% 2.91% | SMA200 | 10.48% ($4.21) | Avg Volume(3M) | 1.06M | Price | $4.65 |
| IPO | 2020/11/9 | Option/Short | No/Yes | Trades | 4805 | Volume | 714,744 | Change | -4.91% |
💊 Alvotech is a global biopharmaceutical company specializing in the development, manufacturing, and commercialization of biosimilars (generic versions of biologic medicines). The company supplies lower-cost alternatives to high-priced original biologic drugs in specialty therapeutic areas such as immunology and oncology. With a fully integrated, single platform spanning R&D, manufacturing, regulatory affairs, and device assembly, Alvotech highlights its deep technical expertise and faster development speed as key advantages over traditional pharmaceutical companies that treat biosimilars as a side business.
Over the past 1 year, roughly in the middle
41% below its 1-year high.
Traded less than usual. That is 67% of its average volume.
Next earnings report: November 11
9 days to go.
ALVO keeps an operating profit but posts a net loss
Of every $100 in sales, $9.12 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +86.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $369. Peers typically go for $226.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -53.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #27 of 83 in the industry
Based on market cap of $2B.
FAQ
What kind of company is ALVO?
ALVO belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ALVO?
The market cap of ALVO is approximately $1.8B, ranking 2,131 within its sector.
What is the 52-week high and low for ALVO?
ALVO has recorded a 52-week high of $7.92 and a low of $2.94.
